GSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp decreased its position in GSK PLC Sponsored ADR (NYSE:GSK) by 10.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,381 shares of the pharmaceutical company’s stock after selling 506 shares during the quarter. Fifth Third Bancorp’s holdings in GSK were worth $170,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of GSK. Parkside Financial Bank & Trust lifted its holdings in shares of GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock valued at $34,000 after buying an additional 818 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of GSK in the fourth quarter valued at $39,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of GSK in the fourth quarter valued at $40,000. Atala Financial Inc acquired a new stake in shares of GSK in the fourth quarter valued at $45,000. Finally, Whipplewood Advisors LLC acquired a new stake in shares of GSK in the fourth quarter valued at $46,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

GSK has been the subject of several research analyst reports. Berenberg Bank restated a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Finally, BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $37.38.

GSK Trading Down 2.7%

Shares of NYSE GSK opened at $38.66 on Friday. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.67. The company has a market cap of $79.14 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 1.35 and a beta of 0.52. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The business has a fifty day simple moving average of $38.51 and a 200-day simple moving average of $36.79.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. GSK’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 earnings per share. Sell-side analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a $0.4216 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.36%. The ex-dividend date of this dividend is Friday, May 16th. GSK’s dividend payout ratio is currently 87.11%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.